title: The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
abstract: BACKGROUND
  Consensus is lacking as to whether the exon 3-deleted (d3)/full-length (fl) GH receptor (GHR) polymorphism is associated with responsiveness to GH therapy.
  
  
  OBJECTIVE
  Our objective was to evaluate, in short, prepubertal, appropriate-for-gestational age (AGA) patients, 2-yr growth response to GH therapy (31.7+/-3.5 microg/kg.d) according to exon 3-deleted/full-length GHR genotypes.
  
  
  METHODS
  We conducted a retrospective study.
  
  
  METHODS
  We studied 106 short AGA children, 58 boys and 48 girls, 7.8+/-2.3 yr, (d3/d3 n=18, d3/fl n=42, and fl/fl n=46). The GH response to two provocative stimuli were under 10 ng/ml in 65 and one or both over 10 ng/ml in 41 patients.
  
  
  METHODS
  Patients were followed by a single clinical team and remained prepubertal during the study. The exon 3-deleted/full-length GHR genotypes were determined and analyzed in the same hospital.
  
  
  RESULTS
  Growth velocity significantly (P<0.0001) increased during the first and second years of therapy, as did height sd score (SDS). These increases were similar in each exon 3-deleted/full-length GHR genotype. Total 2-yr height gain (SDS) did not differ statistically among genotypes: 15.5+/-2.2 cm and 1.2+/-0.5 SDS in d3/d3, 15.9+/-2.0 cm and 1.3+/-0.4 SDS in d3/fl, and 15.4+/-2.1 cm and 1.1+/-0.3 SDS in fl/fl. No significant differences among the three genotypes were found in both sexes or in patients with different GH peak response to provocative stimuli for these parameters. An analysis of previously published studies was also performed.
  
  
  CONCLUSIONS
  These results confirm in AGA patients those previously found by us and others in small-for-gestational-age patients and suggest that neither sex nor GH peaks after provocative stimuli might influence significantly the responsiveness to GH therapy according to the exon 3-deleted/full-length GHR genotypes.
authors.affiliation: Department of Pediatrics, Institut de Recerca, Hospital Vall d'Hebron, Centre for Biomedical Research on Rare Diseases, Autonomous University, Barcelona, Spain. ancarrascosa@vhebron.net
authors.forename: A
authors.initials: A
authors.lastname: Carrascosa
authors.forename: L
authors.initials: L
authors.lastname: Audí
authors.forename: M
authors.initials: M
authors.lastname: Fernández-Cancio
authors.forename: C
authors.initials: C
authors.lastname: Esteban
authors.forename: P
authors.initials: P
authors.lastname: Andaluz
authors.forename: E
authors.initials: E
authors.lastname: Vilaró
authors.forename: M
authors.initials: M
authors.lastname: Clemente
authors.forename: D
authors.initials: D
authors.lastname: Yeste
authors.forename: M A
authors.initials: MA
authors.lastname: Albisu
authors.forename: M
authors.initials: M
authors.lastname: Gussinyé
mesh_terms: D001724:Birth Weight; D001827:Body Height / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D005091:Exons; D005260:Female; D005838:Genotype; D006130:Growth Disorders / Q000188:drug therapy / Q000235:genetics*; D013006:Growth Hormone / Q000627:therapeutic use*; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011110:Polymorphism, Genetic; D011986:Receptors, Somatotropin / Q000235:genetics*; D012189:Retrospective Studies
chemical_list: D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D013006:Growth Hormone